Close navigation

Developing drugs against a tumour-causing protein in glioblastoma

Fast facts

  • Official title: New drug development for glioblastoma
  • Lead researcher: Dr Arezu Jahani-Asl
  • Where: Lady Davis Institute for Medical Research and Jewish General Hospital, Montreal, Canada
  • When: May 2017 - August 2018
  • Cost: £99,722
  • Research type: Adult, Glioblastoma (High Grade), Academic

Dr Jahani-Asl and her team are the first to show that a protein called OSMR drives the growth of glioblastoma tumours.

Therefore, in this research project, the team aims to design and create two different types of drugs to target and inhibit OSMR activity, opening up a new potential therapeutic option that has not yet been explored.

They will also be looking at how OSMR interacts with another tumour causing protein called EGFRvIII, so that this interaction can be disrupted to halt tumour growth.

Research is just one other way your regular gift can make a difference

Research is the only way we will discover kinder, more effective treatments and, ultimately, stamp out brain tumours – for good! However, brain tumours are complex and research in to them takes a great deal of time and money.

Across the UK, over 100,000 families are facing the overwhelming diagnosis of a brain tumour and it is only through the generosity of people like you can we continue to help them.

But, by setting up a regular gift – as little as £2 per month - you can ensure that families no longer face this destructive disease.

Donate today